{"groups":[{"description":"Participants randomized to this arm received the study drug, tivozanib hydrochloride.","id":"FG000","title":"Tivozanib Hydrochloride"},{"description":"Participants randomized to this arm received the comparator drug, sorafenib.","id":"FG001","title":"Sorafenib"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"6"}],"type":"Randomized but not treated"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"175"},{"groupId":"FG001","numSubjects":"175"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"173"},{"groupId":"FG001","numSubjects":"169"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"6"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"preAssignmentDetails":"A total of 350 participants were randomised and 343 were treated."}